Business Wire

SAB Biotherapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of SAB-185 for the Treatment of COVID-19

Share

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce targeted polyclonal antibodies, today announced the dosing of the first patient in its Phase 1b clinical trial evaluating the safety and pharmacological activity of SAB-185, a COVID-19 therapeutic. SAB-185, developed from SAB’s novel technology platform that leverages the native human immune response to offer a differentiated high-potency therapeutic option that potentially addresses virus mutations, is currently being tested in an ongoing Phase 1 trial in healthy volunteers for the treatment of COVID-19.

“We believe that SAB-185 has the potential to be a differentiated treatment option that provides a highly-specific match against the complexity, diversity, and mutations of SARS-CoV-2. Dosing the first patient in this study marks a major milestone for us as we continue to advance our robust COVID-19 program and represents a step forward in the fight against the ongoing global health crisis,” said Eddie J. Sullivan, PhD, co-founder, president and CEO of SAB Biotherapeutics. “The speed with which we have advanced our program reflects our deep understanding of human polyclonal antibodies, the pressing need for treatment options, and the commitment of our team to develop a novel class of immunotherapies that is designed to establish a responsive model for health crises. We look forward to continuing to progress our COVID-19 program, and developing rapid response capabilities to new and emerging diseases.”

SAB-185, a human polyclonal antibody therapeutic that potently neutralizes live SARS-CoV-2 at titers higher than convalescent plasma, was developed from SAB’s proprietary DiversitAb™ platform, which harnesses the native human immune response to produce human polyclonal antibodies. SAB’s novel approach, which leverages genetically engineered cattle to produce fully human antibodies, enables a scalable and reliable production of targeted, high potency neutralizing antibody product. This approach has expedited the rapid development of this novel immunotherapy for COVID-19 deploying the same natural immune response to fight the disease as recovered patients, but with a much higher concentration of targeted antibodies.

The Phase 1b clinical trial is a randomized, double-blind, ascending dose study of SAB-185 administered intravenously in 21 patients with mild or moderate COVID-19. The primary endpoint of the study is safety. The secondary endpoints include an evaluation of the course of mild and moderate COVID-19 in ambulatory patients. Data from both the Phase 1 and Phase 1b studies will be used to inform the dosing and design of subsequent Phase 2 safety and efficacy studies. The Phase 1b trial is planned to be conducted at multiple sites including Sanford Health in Sioux Falls, South Dakota.

"We are excited to participate in this clinical trial to investigate the safety of SAB-185, a novel, first-of-its-kind human polyclonal antibody therapeutic candidate for COVID-19,” said David A. Pearce, PhD, president of innovation and research at Sanford Health.

“Our goal is to advance the science around COVID-19 so physicians can be better prepared to treat this novel coronavirus in the future,” said Dr. Susan Hoover, principal investigator and an infectious disease physician at Sanford Health. “This therapeutic would be an early-stage treatment that could potentially improve our patients' outcomes and even keep them out of the hospital.”

Direct support for the Phase 1 and Phase 1b clinical trials of SAB-185 is provided by the U.S. Department of Defense’s (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) on behalf of the Office of the Assistant Secretary of Defense for Health Affairs (OASD(HA)) and the Defense Health Agency (DHA).  For more information on the Phase 1b trial, please visit https://clinicaltrials.gov (Identifier: NCT04469179).

About SAB-185

SAB-185 is a fully-human, specifically targeted and broadly neutralizing polyclonal antibody therapeutic candidate for COVID-19. The therapeutic was developed from SAB’s novel proprietary DiversitAb™ Rapid Response Antibody Program in collaboration with the USG. CSL Behring is engaged for clinical manufacturing for the definitive trials. SAB filed the Investigational New Drug (IND) application and produced the initial clinical doses in just 98 days from program initiation. The novel therapeutic, generated from a subunit of the SARS-CoV-2 Wuhan strain, has shown neutralization of both the Munich and Washington strains in preclinical studies. Preclinical data has also demonstrated SAB-185 to be more potent than human-derived convalescent immunoglobulin G (IgG).

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. Utilizing some of the most complex genetic engineering and antibody science in the world, SAB has developed a unique platform that can rapidly produce natural, specifically-targeted, high-potency, human polyclonal immunotherapies at commercial scale. SAB-185, a fully-human polyclonal antibody therapeutic candidate for COVID-19, is being developed with initial funding supported by the Biomedical Advanced Research Development Authority (BARDA), part of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services and the Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO - CBRND) Joint Project Lead for Enabling Biotechnologies (JPL-EB). In addition to COVID-19, the company’s pipeline also includes programs in Type 1 diabetes, organ transplant and influenza. For more information visit: www.sabbiotherapeutics.com or follow @SABBantibody on Twitter.

Contact information

Melissa Ullerich
Tel: 605-695-8350
mullerich@sabbiotherapeutics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EURid-Coordinated Dynamic Coalition on Data and Trust Officially Launched24.9.2020 14:00:00 EESTPress release

EURid today announces the launch of a new Dynamic Coalition on Data and Trust (DC-DT) for the 2020 Internet Governance Forum. In recent years, disinformation scandals and increasing levels of consolidation in technology markets have diminished the confidence of regulators and members of the public in the effectiveness of industry self-regulation. The Dynamic Coalition will deepen understanding of these issues and build consensus among interested stakeholders. The new group is a partnership with multiple stakeholders across the private, public and civil society sectors including European Commission, Europol and the Computational Propaganda Unit at Oxford University’s Internet Institute and members of the International Trade Mark Association. The key aims and activities of the Coalition will include: 1. Exploring linkages between data and trust to inform policy discussions with a solid evidence base and showcase relevant research which explores linkages between data, information and trus

Best Buy, McKinstry, Real Betis, Schneider Electric, and Siemens Sign The Climate Pledge24.9.2020 13:00:00 EESTPress release

Today, Amazon (NASDAQ: AMZN) and Global Optimism announced that Best Buy, McKinstry, Real Betis, Schneider Electric, and Siemens have joined The Climate Pledge , a commitment to be net-zero carbon by 2040—a decade ahead of the Paris Accord’s goal of 2050. These new signatories to The Climate Pledge agree to: Measure and report greenhouse gas emissions on a regular basis; Implement decarbonization strategies in line with the Paris Agreement through real business changes and innovations, including efficiency improvements, renewable energy, materials reductions, and other carbon emission elimination strategies; Neutralize any remaining emissions with additional, quantifiable, real, permanent, and socially-beneficial offsets to achieve net-zero annual carbon emissions by 2040. “From hurricanes to forest fires, climate change is leading to very real, negative impacts to our daily lives even sooner than scientists expected. Every company has a role to play in fighting climate change, and we

Universal Peace Federation (UPF) Holds 2nd Online “Rally of Hope”24.9.2020 12:57:00 EESTPress release

The Universal Peace Federation (UPF) is announcing that a second global Rally of Hope will be held this weekend, featuring world leaders who see new opportunities for peacebuilding in all sectors of society. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200924005400/en/ Universal Peace Federation (UPF) holds 2nd Online “Rally of Hope”. Global leaders come together for peace based on ideals of interdependence, mutual prosperity and universal values. (Photo: Business Wire) Dr. Hak Ja Han Moon, co-Founder of the Universal Peace Federation, will be the keynote speaker. Other luminaries include Sao Tome and Principe President Evaristo Carvalho; U.S. Vice President Dan Quayle (1989-1993); former European Commission Chairman Jose Manuel Barroso (2004-2014); Nigeria President Goodluck Jonathan (2010-2015); Evangelical Lutheran Church Bishop (Emeritus) Munib Younan; and Roman Catholic Archbishop (Emeritus) of Castries Kelvin Edward

NanoTemper Technologies Launches DLS Capability With Prometheus Panta, Bringing High-Resolution, Domain-Specific Stability Characterization to Biologics24.9.2020 12:48:00 EESTPress release

NanoTemper Technologies, well-known for creating tools that address challenging characterizations, today introduced Prometheus Panta, a multi-parameter stability characterization instrument. By combining DLS for particle size determination with nanoDSF for thermal unfolding and backreflection for aggregation, researchers in biologics formulation optimization, developability, or comparability assessments will find that Prometheus Panta offers superior characterization of their candidate molecules. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200924005395/en/ (Photo: Business Wire) “Inevitably, researchers will come across candidate molecules that present challenges. Here’s where Prometheus Panta shines, offering a solution they can rely on for clear, trustworthy, and high-resolution data for colloidal and conformational stability,” said Philipp Baaske, Co-CEO of NanoTemper. Having the right technology really matters when re

Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR Modulators24.9.2020 12:25:00 EESTPress release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data from the company’s portfolio of cystic fibrosis (CF) medicines will be presented at the 43rd European Cystic Fibrosis Digital Conference (ECFS) held September 24-25, 2020 and the 2020 North American Cystic Fibrosis Virtual Conference (NACFC) taking place October 7-23, 2020. An oral presentation at the ECFS Digital Conference will highlight, for the first time, interim results from the TRIKAFTA open-label extension study, which showed safety and efficacy consistent with the results of the Phase 3 pivotal studies in patients with CF ages 12 and older with F508del/Minimal Function (F/MF) or F508del/F508del (F/F) genotypes. Four additional scientific abstracts for ORKAMBI® and TRIKAFTA® were published in the Journal of Cystic Fibrosis as part of the ECFS conference. In addition, six scientific presentations will occur at NACFC regarding KALYDECO,® ORKAMBI and TRIKAFTA, including new data from KALYDECO in infants a

Ant Group’s INCLUSION Fintech Conference Debuts in Shanghai24.9.2020 12:00:00 EESTPress release

Ant Group, an innovative technology provider, today officially launched its inaugural INCLUSION Fintech Conference, welcoming prominent speakers from all corners of the world, including representatives from the United Nations and the International Monetary Fund, as well as Nobel Prize-winning scholars, to participate in a wide-ranging conversation on how digital technology can help build a more inclusive, green, and sustainable world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200924005369/en/ IMF Managing Director Kristalina Georgieva delivers keynote speech at inaugural INCLUSION Fintech Conference (Photo: Business Wire) Taking place both online and onsite in Shanghai from September 24-26, 2020, the conference brings together thought leaders from across the globe to envision the digital economy of the future. The first day of the conference began with a morning plenary session, followed by 17 forums in the afternoon an

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom